SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: mark montgomery who wrote (41)9/26/1996 1:35:00 AM
From: Sean Janzen   of 1501
 
Mark,

Has anyone responded to your question regarding studies comparing coricosteroids to Apanol (even in in vitro or early animal work)? Did you fax your question to James King?

The answer to your question is found in the article by First Honolulu Securities, Inc, found under "NEWS" on Inflazyme's home page at
stockprofiles.com

" Apanol (IZP-94005) is a small, orally bioavailable compound, with a steroid-like structure. It has an unusual hemi-acetyl side chain, and is also highly oxygenated.

In animals, it possesses significant antiinflammatory properties and prevents allergic reactions when given either by inhalation or orally, and is at least as potent as corticosteroids in its antihistamine properties. It also prevented the acute and late phase asthmatic reactions. Inflammatory cell infiltration is inhibited significantly.

It did not interfere with glucocorticoid receptors, inhibit the HPA axis, or cause cardiotoxicity. It is not immunosuppresive. As might be expected by these results, systemic corticosterone levels were not affected while similar doses of steroids suppressed levels 95%."

Does this answer your question? Maybe you should call the company to obtain the studies used to make such claims. Let us know what you come up with.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext